Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials

Author： Ciardiello Fortunato De Vita Ferdinando Orditura Michele De Placido Sabino Tortora Giampaolo

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.8, Iss.2, 2003-11, pp. : 501-514

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1613-1628

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily: Role as Anticancer Agents

By Noonberg S.B. Benz C.C.

Drugs, Vol. 59, Iss. 4, 2000-04 ,pp. : 753-767

Adis International

Access to resources Recommend Favorite

Design, Synthesis and Biological Evaluation of Salicylamide Analogues as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Letters in Drug Design & Discovery, Vol. 13, Iss. 4, 2016-05 ,pp. : 314-323

Bentham Science Publishers

Access to resources Recommend Favorite

Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 851-864

Bentham Science Publishers

Access to resources Recommend Favorite